Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.81 |
| ▸ | CNR2 | P34972 | 10/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2023856 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL5444990 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL29375695 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL8452745 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL2018977 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4608199 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL2419758 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL8470688 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL674917 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| Hydrochloric Acid SCHEMBL4551016 | 0.99 | CNR1 (0.80) | CNR1CNR2ABCC4MLNRABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968582-B2 | 5(S)-substituted pyrazoline compounds, their preparation and use as medicaments | LABOROTORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-28 | — | — | US | claimed |
| EP-2042175-A1 | Dose regimens of CB1-Receptor ligands in the treatment of obesity | Laboratorios del Dr. Esteve S.A. (ES) | 2009-04-01 | — | — | EP | claimed |
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1946778-A1 | Active substance combination for the treatment of diabetes | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | claimed |
| EP-1944295-A1 | Non-racemic mixtures of (R)-N-piperidinyl-5-(4-chlorophenyl)1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-16 | — | — | EP | claimed |
| EP-1910332-A2 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | claimed |
| EP-1907365-A1 | SALTS OF SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-09 | — | — | EP | claimed |
| EP-1749526-A1 | Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-07 | — | — | EP | claimed |
| EP-1749527-A1 | Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-07 | — | — | EP | claimed |
| EP-1749820-A1 | Salts of substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-07 | — | — | EP | claimed |
| WO-2007009708-A1 | SALTS OF SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009706-A2 | SUBSTITUTED PYRAZOLINE COMPOUNDS, HAVING PREDETERMINED STEREOCHEMISTRY, FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009686-A2 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009704-A2 | USE OF SUBSTITUTED PYRAZOLINE COMPOUNDS FOR THE TREATMENT OF FOOD DISORDERS, INCLUDING OBESITY OR METABOLIC SYNDROME IN PATIENTS WITH DEVELOPED DIABETES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | claimed |
| EP-1746090-A1 | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-24 | — | — | EP | claimed |
| US-20070015811-A1 | 5(S)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-18 | — | — | US | claimed |
| EP-1743643-A1 | New formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743639-A1 | Use of substituted pyrazoline compounds for the treatment of coagulation related diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743892-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743889-A1 | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015811-A1 | 5(S)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | CYP3A5, P2RX5, PPIP5K2 | CNR1 831/4885CNR2 597/4885ABCC4 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.